Incannex Healthcare
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- -
- Employees
- 10
- Market Cap
- $34.7M
- Introduction
Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on July 5, 2023 and is headquartered in Norwes...
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
Incannex Healthcare secured up to $59.0 million USD in strategic financing, reported positive Phase 2 PsiGAD1 trial results for PSX-001, initiated dosing in RePOSA Phase 2/3 trial for IHL-42X, received FDA IND clearance for PsiGAD2, and completed redomiciliation to the U.S. with Nasdaq listing under 'IXHL'.
Incannex $60 Million Deal With Arena For Late-Stage Drug Trials
Incannex Healthcare Inc. secured up to $60 million in funding from Arena Investors, including $10 million in convertible notes and a $50 million equity line of credit, to advance clinical trials for its cannabinoid and psychedelic-assisted therapeutics targeting chronic conditions.
© Copyright 2024. All Rights Reserved by MedPath